Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from BioMarin Pharmaceutical ( (BMRN) ).
On May 20, 2025, BioMarin Pharmaceutical Inc. held its Annual Meeting of Stockholders, where stockholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 8,000,000. This amendment, effective immediately, was previously approved by the Compensation Committee, indicating strong internal support for expanding equity incentives. Additionally, stockholders elected ten directors, ratified KPMG LLP as the independent registered public accounting firm, and approved executive compensation, reflecting continued confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (BMRN) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.
Spark’s Take on BMRN Stock
According to Spark, TipRanks’ AI Analyst, BMRN is a Outperform.
BioMarin Pharmaceutical is positioned strongly due to its robust financial performance and strategic acquisition, which enhances its growth potential. However, bearish technical indicators suggest caution in the short term. The company is reasonably valued given its growth prospects, with positive sentiment from the earnings call underscoring its strategic positioning and operational strength. The outlook remains optimistic, though investors should be mindful of technical trends and potential risks related to VOXZOGO’s revenue dynamics and tariff exposure.
To see Spark’s full report on BMRN stock, click here.
More about BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. operates in the biotechnology industry, focusing on developing and commercializing innovative therapies for serious and life-threatening rare genetic diseases.
Average Trading Volume: 1,784,023
Technical Sentiment Signal: Sell
Current Market Cap: $11.49B
For an in-depth examination of BMRN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue